AstraZeneca To Buy US-based Icosavax In Around $1.1 Bln Deal
British drug major AstraZeneca Plc. (AZN.L,AZN) announced Tuesday that it has entered into a definitive agreement to acquire Icosavax, Inc. (ICVX), a US-based clinical-stage biopharmaceutical company, for a transaction value of around $1.1 billion. Under the deal terms, AstraZeneca, through a subsidiary, will initiate a tender offer to acquire Icosavax shares for $15.00 per share in cash at closing. The […]
Read more